An evidence-based review of risk-reductive strategies for osteonecrosis of the jaws among cancer patients

Current Clinical Pharmacology

Volumn 8, Issue 2, 2013, Pages 124-134

  Kyrgidis, Athanassios ^a   Tzellos, Thrasivoulos George ^a   Toulis, Konstantinos ^b   Arora, Amit ^c   Kouvelas, Dimitrios ^a   Triaridis, Stefanos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b 424 General Army Hospital   (Greece)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Bisphosphonate; Denosumab; Meta analysis; Oncology; Osteonecrosis of the jaw; Risk reduction

Indexed keywords

CLODRONIC ACID; DENOSUMAB; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; VITAMIN D; ZOLEDRONIC ACID;

ADVANCED CANCER; BONE METASTASIS; CANCER PATIENT; CLINICAL EFFECTIVENESS; COCHRANE LIBRARY; COHORT ANALYSIS; DRUG EXPOSURE; EMBASE; HUMAN; JAW OSTEONECROSIS; LOADING DRUG DOSE; MEDLINE; OSTEOLYSIS; PERIODONTAL DISEASE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SMOKING; SYSTEMATIC REVIEW; TOOTH EXTRACTION; TOOTH PROSTHESIS; TOOTH ROOT CANAL; VITAMIN SUPPLEMENTATION;

BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE RESORPTION; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; EVIDENCE-BASED MEDICINE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84876869277     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574884711308020005     Document Type: Review

References (51)

1. Coleman RE. Risks and benefits of bisphosphonates. Br J Cancer2008; 98: 1736-40.
2. Anastasilakis AD, Toulis KA, Polyzos SA, Terpos E. RANKLinhibition for the management of patients with benign metabolicbone disorders. Expert Opin Investig Drugs 2009; 18: 1085-102.
3. Van Poznak CH, Temin S, Yee GC, et al. American Society ofClinical Oncology Executive Summary of the Clinical PracticeGuideline Update on the Role of Bone-Modifying Agents inMetastatic Breast Cancer. J Clin Oncol J Clin Oncol 2011; 29(9):1221-7.
4. Kyrgidis A, Triaridis S, Vahtsevanos K, Antoniades K. Osteonecrosis of the jaw and bisphosphonate use in breast cancerpatients. Expert Rev Anticancer Ther 2009; 9: 1125-34.
5. Edwards BJ, Gounder M, McKoy JM, et al. Pharmacovigilance andreporting oversight in US FDA fast-track process: bisphosphonatesand osteonecrosis of the jaw. Lancet Oncol 2008; 9: 1166-72.
6. Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS. Intravenousbisphosphonate therapy and inflammatory conditions or surgery ofthe jaw: a population-based analysis. J Natl Cancer Inst 2007; 99:1016-24.
7. Ruggiero SL, Dodson TB, Assael LA, et al. American Associationof Oral and Maxillofacial Surgeons Position Paper onBisphosphonate-Related Osteonecrosis of the Jaws--2009 Update. JOral Maxillofacial Surg 2009; 67: 2-12.
8. Bagan JV, Jimenez Y, Diaz JM, et al. Osteonecrosis of the jaws inintravenous bisphosphonate use: Proposal for a modification of theclinical classification. Oral Oncol 2009; 45: 645-6.
9. Pazianas M, Miller P, Blumentals WA, Bernal M, KothawalaP. A review of the literature on osteonecrosis of the jaw inpatients with osteoporosis treated with oral bisphosphonates:prevalence, risk factors, and clinical characteristics. Clin Ther 2007;29: 1548-58.
10. Kyrgidis A, Triaridis S, Antoniades K, Effects of bisphosphonateson keratinocytes and fibroblasts may have a role in thedevelopment of osteonecrosis of the jaw. Biosci Hypotheses 2009;2: 153-159.
11. Pazianas M. Osteonecrosis of the Jaw and the Role of MacrophagesJ Natl Cancer Inst 2011; 103: 232-240.
12. Kyrgidis A, Andreadis C. Clinical characterization might help inpreventing osteonecrosis of the jaw. Clin Cancer Res 2008; 14:8321.
13. Dimopoulos MA, Kastritis E, Bamia C, et al. Reduction ofosteonecrosis of the jaw (ONJ) after implementation of preventivemeasures in patients with multiple myeloma treated with zoledronicacid. Ann Oncol 2009; 20: 117-20.
14. Estilo CL, Van Poznak CH, Wiliams T, et al. Osteonecrosis of themaxilla and mandible in patients with advanced cancer treated withbisphosphonate therapy. Oncologist 2008; 13: 911-20.
15. Hoff AO, Toth BB, Altundag K, et al. Frequency and risk factorsassociated with osteonecrosis of the jaw in cancer patients treatedwith intravenous bisphosphonates. J Bone Miner Res 2008; 23:826-36.
16. Ripamonti CI, Maniezzo M, Campa T, et al. Decreased occurrenceof osteonecrosis of the jaw after implementation of dentalpreventive measures in solid tumour patients with bone metastasestreated with bisphosphonates. The experience of the NationalCancer Institute of Milan. Ann Oncol 2009; 20: 137-45.
17. Vahtsevanos K, Kyrgidis A, Verrou E, et al. Longitudinal CohortStudy of Risk Factors in Cancer Patients of Bisphosphonate-RelatedOsteonecrosis of the Jaw. J Clin Oncol 2009; 27: 5356-5362.
18. Kyrgidis A, Triaridis S. Comment on: Bony changes in the jaws ofrats treated with zoledronic acid and dexamethasone before dentalextractions mimic bisphosphonate-related osteonecrosis in cancerpatients. Oral Oncol 2009; 45: e38.
19. Fedele S, Kumar N, Davies R, Fiske J, Greening S, Porter S. Dentalmanagement of patients at risk of osteochemonecrosis of the jaws:a critical review. Oral Dis 2009; 15: 527-537.
20. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonateinducedexposed bone (osteonecrosis/osteopetrosis) of the jaws:risk factors, recognition, prevention, and treatment. J OralMaxillofac Surg 2005; 63: 1567-75.
21. Kyrgidis A, Tzellos T-G, Toulis K, Antoniades K. The facialskeleton in patients with osteoporosis: a field for disease signs andtreatment complications. J Osteoporos 2011; 2011: 147689.
22. Hokugo A, Christensen R, Chung E, et al. Increased prevalence ofbisphosphonate-related osteonecrosis of the jaw with vitamin Ddeficiency in rats. J Bone and Mineral Res 2010; 9999: n/a.
23. Malden N, Beltes C, Lopes V. Dental extractions and bisphosphonates:the assessment, consent and management, a proposed algorithm. BrDent J 2009; 206: 93-8.
24. Kyrgidis A, Arora A, Lyroudia K, Antoniades K. Root canaltherapy for the prevention of osteonecrosis of the jaws: anevidence-based clinical update. Aust Endod J 2010; 36: 130-3.
25. Kyrgidis A, Vahtsevanos K, Koloutsos G, et al. Biphosphonaterelated osteonecrosis of the jaws: risk factors in breast cancerpatients. A case control study. J Clin Oncol 2008; 26: 4634-8.
26. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality ofreports of randomized clinical trials: Is blinding necessary?. Controlled Clin Trials 1996; 17: 1-12.
27. Wells GA, Shea B, O'Connell D, et al. The Newcastle-OttawaScale (NOS) for assessing the quality of nonrandomised studies inmeta-analyses. 2010 [Updated; Accessed 12 March 2010. Availablefrom: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm
28. Anastasilakis AD, Toulis KA, Goulis DG, et al. Efficacy and safetyof denosumab in postmenopausal women with osteopenia orosteoporosis: a systematic review and a meta-analysis. HormMetab Res 2009; 41: 721-9.
29. Higgins J, Green S, eds. Cochrane Handbook for SystematicReviews of Interventions Version. 5.1.0. Vol. Available from www. cochrane-handbook.org, 2012ed. The Cochrane Collaboration 2012.
30. Fizazi K, Carducci M, Smith M, et al. Denosumab versuszoledronic acid for treatment of bone metastases in men withcastration-resistant prostate cancer: a randomised, double-blindstudy. Lancet 2011; 377(9768): 813-22.
31. Henry DH, Costa L, Goldwasser F, et al. Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in theTreatment of Bone Metastases in Patients With Advanced Cancer(Excluding Breast and Prostate Cancer) or Multiple Myeloma. JClin Oncol 2011; 29(9): 1125-32.
32. Morgan GJ, Davies FE, Gregory WM, et al. First-line treatmentwith zoledronic acid as compared with clodronic acid in multiplemyeloma (MRC Myeloma IX): a randomised controlled trial. TheLancet 2010; 376: 1989-99.
33. Stopeck AT, Lipton A, Body J-J, et al. Denosumab Compared WithZoledronic Acid for the Treatment of Bone Metastases in PatientsWith Advanced Breast Cancer: A Randomized, Double-BlindStudy. J Clin Oncol 2010; 28: 5132-5139.
34. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine Therapyplus Zoledronic Acid in Premenopausal Breast Cancer. NewEngland J Med 2009; 360: 679-691.
35. Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronicacid in postmenopausal women with early breast cancer receivingadjuvant letrozole: 36-month results of the ZO-FAST Study. AnnOncol 2010; 21: 2188-2194.
36. Gimsing P, Carlson K, Turesson I, et al. Effect of pamidronate 30mg versus 90 mg on physical function in patients with newlydiagnosed multiple myeloma (Nordic Myeloma Study Group): adouble-blind, randomised controlled trial. Lancet Oncol 2010; 11:973-82.
37. Coleman RE. Clinical features of metastatic bone disease and riskof skeletal morbidity. Clin Cancer Res 2006; 12: 6243s-6249s.
38. Pazianas M, Cooper C, Ebetino FH, Russell RGG. Long-termtreatment with bisphosphonates and their safety in postmenopausalosteoporosis. Ther Clin Risk Manag 2010; 6: 325-43.
39. Russell RG, Xia Z, Dunford JE, et al. Bisphosphonates: an updateon mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 2007; 1117: 209-57.
40. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) inducedavascular necrosis of the jaws: a growing epidemic. J OralMaxillofac Surg 2003; 61: 1115-7.
41. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-inducedosteonecrosis: risk factors, prediction of risk using serum CTXtesting, prevention, and treatment. J Oral Maxillofac Surg 2007; 65:2397-410.
42. Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treatedwith bisphosphonates: evidence of increased risk after treatmentwith zoledronic acid. Haematologica 2006; 91: 968-971.
43. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw andbisphosphonates. N Engl J Med 2005; 353: 99-102.
44. Garcia Saenz JA, Lopez TS, Garcia PB. Osteonecrosis of the jaw asan adverse bisphosphonate event: three cases of bone metastaticprostate cancer patients treated with zoledronic acid. Med OralPatol Oral Cir Bucal 2007; 12(5): E351-6.
45. Kyrgidis A, Vahtsevanos K. A safe modality. Br Dent J 2009; 206:561; author reply 562.
46. Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors andmanagement of osteonecrosis of the jaw in patients with multiplemyeloma: a single-centre experience in 303 patients. Br J Haematol2006; 134: 620-623.
47. Kyrgidis A, Toulis KA. Denosumab-Related Osteonecrosis of TheJaws. Osteoporos Int 2010. DOI 10.1007/s00198-010-1177-6.
48. Kyrgidis A. Novel Hypotheses in the Etiopathogenesis ofBisphosphonate-Related Osteonecrosis of the Jaws. J OralMaxillofacial Surg 2009; 67: 2554.
49. Machado M, Cruz LS, Tannus G, Fonseca M. Efficacy ofclodronate, pamidronate, and zoledronate in reducing morbidityand mortality in cancer patients with bone metastasis: A metaanalysisof randomized clinical trials. Clin Ther 2009; 31: 962-979.
50. Kyrgidis A, Tzellos T-G. Safety and efficacy of zoledronic acid inmultiple myeloma. The Lancet 2011; 377: 2177-2178.
51. ZOMETA Safety & Tolerability: Dental Health. 2011 [Updated;Accessed March, 28, 2011. Available from: http://www.zometa.com/safety-tolerability/onj-is-uncommon.jsp